论文信息 - Delivery of urethral sphincter botulinum toxin injections for treating urinary retention during the COVID19 pandemic - 字舞流文

Delivery of urethral sphincter botulinum toxin injections for treating urinary retention during the COVID19 pandemic

P. Ananthavarathan | J. Panicker | P. Malladi | S. Simeoni | M. Pakzad | Sarah L. Wright | Madhumita R. Satish

[1] Yuan-Hong Jiang,et al. Therapeutic Effects of Urethral Sphincter Botulinum Toxin A Injection on Dysfunctional Voiding with Different Videourodynamic Characteristics in Non-Neurogenic Women , 2021, Toxins.

[2] I. Scott,et al. Impact of COVID-19 pandemic on utilisation of healthcare services: a systematic review , 2021, BMJ Open.

[3] T. Kessler,et al. Open‐label study evaluating outpatient urethral sphincter injections of onabotulinumtoxinA to treat women with urinary retention due to a primary disorder of sphincter relaxation (Fowler's syndrome) , 2016, BJU international.

[4] N. Osman,et al. Fowler's syndrome—a cause of unexplained urinary retention in young women? , 2014, Nature Reviews Urology.

[5] T. Kessler,et al. The possible role of opiates in women with chronic urinary retention: observations from a prospective clinical study. , 2012, The Journal of urology.

[6] N. Kitchen,et al. Sacral Neuromodulation for Women with Fowler’s Syndrome , 2000, European Urology.